Westfield Capital Management Co. LP Purchases 300 Shares of Danaher Corporation $DHR

Westfield Capital Management Co. LP boosted its position in shares of Danaher Corporation (NYSE:DHR) by 1.9% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 16,110 shares of the conglomerate’s stock after acquiring an additional 300 shares during the quarter. Westfield Capital Management Co. LP’s holdings in Danaher were worth $3,182,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Artisan Partners Limited Partnership raised its holdings in shares of Danaher by 29.8% in the 2nd quarter. Artisan Partners Limited Partnership now owns 2,672,971 shares of the conglomerate’s stock valued at $528,019,000 after purchasing an additional 612,894 shares during the period. Saturna Capital Corp bought a new position in Danaher during the second quarter worth about $459,000. Empirical Finance LLC increased its position in Danaher by 0.6% during the second quarter. Empirical Finance LLC now owns 22,791 shares of the conglomerate’s stock worth $4,502,000 after buying an additional 147 shares during the last quarter. Sierra Legacy Group raised its stake in Danaher by 83.8% in the second quarter. Sierra Legacy Group now owns 5,505 shares of the conglomerate’s stock valued at $1,087,000 after buying an additional 2,510 shares during the period. Finally, Primecap Management Co. CA lifted its position in shares of Danaher by 924.2% in the second quarter. Primecap Management Co. CA now owns 1,239,320 shares of the conglomerate’s stock valued at $244,815,000 after buying an additional 1,118,318 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Analysts Set New Price Targets

DHR has been the topic of a number of recent analyst reports. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Danaher in a report on Wednesday, October 8th. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a research report on Thursday, October 23rd. Barclays lifted their target price on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a report on Wednesday, October 22nd. Finally, TD Cowen increased their price target on shares of Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a report on Wednesday, October 22nd. Eighteen analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Danaher Stock Performance

Shares of NYSE:DHR opened at $222.44 on Friday. Danaher Corporation has a 12-month low of $171.00 and a 12-month high of $258.23. The company’s 50 day moving average price is $207.83 and its two-hundred day moving average price is $201.76. The firm has a market cap of $157.12 billion, a PE ratio of 45.86, a PEG ratio of 3.28 and a beta of 0.81. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.72 by $0.17. The business had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a return on equity of 10.92% and a net margin of 14.44%.The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. During the same period in the previous year, the company posted $1.71 earnings per share. Equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were issued a dividend of $0.32 per share. This represents a $1.28 annualized dividend and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s dividend payout ratio is 26.39%.

Insider Buying and Selling

In other Danaher news, SVP Brian W. Ellis sold 21,776 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $219.23, for a total value of $4,773,952.48. Following the transaction, the senior vice president directly owned 14,553 shares of the company’s stock, valued at $3,190,454.19. This trade represents a 59.94% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the business’s stock in a transaction that occurred on Monday, November 10th. The shares were sold at an average price of $210.42, for a total transaction of $1,088,713.08. Following the completion of the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. The trade was a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 30,248 shares of company stock worth $6,609,663. Company insiders own 11.10% of the company’s stock.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.